Donate For Public and Patients Store Search

F005 - Acne Boot Camp

Friday, March 1; 9:00 AM - 11:00 AM

Learning Objectives

Following this course, the attendee should be able to:

  • Manage acne vulgaris effectively.
  • Select new treatment options more effectively.

Description

This session is directed to dermatologists who treat acne and will cover the basics of acne treatment as well as novel treatment options.

Disclosures

  • Bhatia, Neal D., MD: AbbVie – I(Grants/Research Funding); Aclaris Therapeutics, Inc. – I(Grants/Research Funding); Actavis – I(Grants/Research Funding); Allergan, Inc – C(H); Almirall – C(H); Asana Biosciences, LLC – I(Grants/Research Funding); Atacama Therapeutics – I(Grants/Research Funding); Biofrontera AG – C(H); BioPharmX – I(Grants/Research Funding); BMS – I(Grants/Research Funding); Brickell Biotech, Inc. – I(Grants/Research Funding); Crown Laboratories, Inc. – I(Grants/Research Funding); Cutanea Life Sciences – I(Grants/Research Funding); Dermira – I(Grants/Research Funding); Dr. Reddy – A(Grants/Research Funding); DUSA Pharmaceuticals, Inc. – I(Grants/Research Funding); Ferndale Laboratories, Inc. – C(H); Foamix – I(Grants/Research Funding); Galderma Laboratories, L.P. – C(H); Glenmark Generics Inc. – I(Grants/Research Funding); IntraDerm Pharmaceuticals – C(H); ISDIN – C(H); Kiniksa Pharmaceuticals, Ltd. – I(Grants/Research Funding); La Roche-Posay Laboratorie Pharmaceutique – C(H); LEO Pharma, US – I(Grants/Research Funding); Mayne Pharma Group – C(H); MC2 Therapeutics – I(Grants/Research Funding); Menlo Therapeutics – I(Grants/Research Funding); Naked Biome, Inc. – I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – C(H); Ortho Dermatologics – C(H); Par Pharmaceutical – I(Grants/Research Funding); Perrigo Company – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding); Pierre Fabre Dermo-Cosmétique US – C(H); Promius Pharma, LLC – A(H); Realm Therapeutics – I(Grants/Research Funding); Sanofi/Regeneron – C(H), I(Grants/Research Funding); Sienna Biopharmaceuticals – I(Grants/Research Funding); Skinfix, Inc. – A(H); Sol-Gel Technologies – I(Grants/Research Funding); Soligenix, Inc – I(Grants/Research Funding); Strata Skin Sciences – I(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – C(H); UCB – I(Grants/Research Funding); Valeant Pharmaceuticals International – C(H); Vidac Pharma – I(Grants/Research Funding); Vyome Therapeutics Limited – C(Grants/Research Funding);
  • Del Rosso, James Q., DO: AbbVie – I(Grants/Research Funding); Aclaris Therapeutics Inc. – C(H), I(Grants/Research Funding), SP(H); Almirall – C(H); AnaptysBio – I(Grants/Research Funding); Athenix – I(Grants/Research Funding); BioPharmX – I(Grants/Research Funding); Botanix Pharmaceuticals – I(Grants/Research Funding); Cassiopea S.p.A. – C(H); Celgene Corporation – C(H), I(Grants/Research Funding), SP(H); Cutanea Life Sciences – A(H), I(Grants/Research Funding), SP(H); Dermavant Sciences – A(H); Dermira – C(H), I(Grants/Research Funding), SP(H); Encore Dermatology, Inc. – C(H), SP(H); Ferndale Laboratories, Inc. – C(H); Foamix – A(H), I(Grants/Research Funding); Galderma Laboratories, L.P. – C(H), I(Grants/Research Funding), SP(H); Genentech, Inc. – SP(H); L'Oreal USA Inc. – A(H); La Roche-Posay Laboratorie Pharmaceutique – C(H); Leo Pharma Inc. – C(H), I(Grants/Research Funding); LEO Pharma, US – SP(H); Mayne Pharma Group – A(H), SP(H); Menlo Therapeutics – A(H), I(Grants/Research Funding); Novan – C(H), I(Grants/Research Funding); Ortho Dermatologics – C(H), I(Grants/Research Funding); Othro Dermatologics – SP(H); Pfizer Inc. – A(H), SP(H); Promius Pharma, LLC – I(Grants/Research Funding); Ralexar Therapeutics, Inc – I(Grants/Research Funding); Regeneron Pharmaceuticals, Inc. – E(S), SP(H); Sanofi Genzyme – SP(H); Sebacia, Inc. – C(H), I(Grants/Research Funding); Skinfix, Inc. – C(H); Sol-Gel Technologies – C(H), I(Grants/Research Funding); Sonoma Pharmaceuticals – C(H); Sun Pharmaceutical Industries Ltd. – C(H), I(Grants/Research Funding), SP(H); Unilever Home & Personal Care USA – A(H); Verrica Pharmaceuticals Inc – C(H);
  • Harper, Julie Claire, MD: Aclaris Therapeutics Inc. – A(H); Allergan, Inc – SP(H); Aqua – C(H); Bayer Pharmaceuticals – I(Fees), O(H); BioPharmX – A(H); Dermira – A(H); Galderma Laboratories, L.P. – C(H); Galderma USA – SP(H); La Roche-Posay Laboratoire Pharmaceutique – SP(H); Novan – A(H); Promius Pharma, LLC – SP(H); Sun Pharmaceutical Industries Ltd. – C(Fees); Taro Pharm – A(H); Valeant Pharmaceuticals North America LLC – SP(H);
  • Kircik, Leon H., MD: 3M Pharmaceuticals – I(Grants/Research Funding), SP(H); Abbott Laboratories – SP(H); Ablynx – I(Grants/Research Funding); Acambis – I(Grants/Research Funding); Allergan, Inc – A(H), C(H), I(H), SP(H); Almirall – C(H); Amgen – C(H), I(Grants/Research Funding), SP(H); AnaptysBio – I(Grants/Research Funding); Aqua – A(H); Astellas Pharma US, Inc – I(Grants/Research Funding), SP(H); Asubio Pharmaceuticals, Inc. – I(Grants/Research Funding); Bayer Consumer Healthcare Pharmaceuticals – I(Grants/Research Funding); Beiersdorf, Inc. – C(H), I(Grants/Research Funding); Biogen – A(H); Biolife – I(Grants/Research Funding); Biopelle, Inc. – I(Grants/Research Funding); Breckinridge Pharma – I(Grants/Research Funding); Cassiopea SpA – C(H); Centocor Ortho Biotech Inc. – I(Grants/Research Funding); ColBar LifeScience Ltd. – A(H), C(H); CollaGenex Pharmaceuticals, Inc. – C(H), I(Grants/Research Funding), SP(H); Connetics Corporation – A(H), C(H), I(Grants/Research Funding); Coria Laboratories – I(Grants/Research Funding); Dermik Laboratories, a business of sanofi-aventis U.S. LLC – SP(H); Dow Pharmaceutical Sciences, Inc. – I(Grants/Research Funding); DUSA Pharmaceuticals, Inc. – I(Grants/Research Funding); Embil Pharmaceuticals, Co., Ltd – SP(H); EOS – A(H); Ferndale Laboratories, Inc. – A(H), I(Grants/Research Funding); Galderma Laboratories, L.P. – A(H), C(H), I(Grants/Research Funding), SP(H); Genentech, Inc. – A(H), C(H), I(Grants/Research Funding), SP(H); GlaxoSmithKline – I(Grants/Research Funding); Healthpoint – I(Grants/Research Funding); Intendis, Inc. – A(H), C(H), I(Grants/Research Funding); Isdin – A(H); Johnson & Johnson Consumer Products Company – A(H), C(H), I(Grants/Research Funding), SH(ST), SP(H); Laboratory Skin Care, Inc. – C(H); Leo Pharma Inc – C(H), I(Grants/Research Funding), SP(H); Medical International Technologies – C(H); Medicis Pharmaceutical Corporation – I(Grants/Research Funding); Merck & Co., Inc – C(H); Merck Serono – SP(H); Merz Pharmaceuticals, LLC – C(H); NanoBio Corporation – A(H), I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – C(H), I(Grants/Research Funding); Nucryst – I(Grants/Research Funding); Obagi Medical Products – I(Grants/Research Funding); Onset Dermatologics – I(Grants/Research Funding), SP(H); Othro Dermatologics – A(H), C(H), I(Grants/Research Funding), SP(H); Pfizer Inc. – I(Grants/Research Funding); Pharmaderm – I(Grants/Research Funding), SP(H); Promius Pharma, LLC – A(H), C(H), I(Grants/Research Funding); PuraCap Pharmaceutical – C(H); QLT Inc. – I(H); SkinMedica, Inc. – A(H), C(H), I(Grants/Research Funding), SP(H); Stiefel a GSK company – A(H), C(H), I(Grants/Research Funding), SP(H); Sun Pharmaceutical Industries Ltd. – A(H), SP(H); Taro Pharm – C(H), I(Grants/Research Funding); TolerRx – I(Grants/Research Funding); Triax Pharmaceuticals, LLC – C(H), I(Grants/Research Funding), SP(H); Valeant Pharmaceuticals International – A(H), C(H), I(Grants/Research Funding), SP(H); Warner Chilcott – A(H), I(Grants/Research Funding), SP(H); Xenoport, Inc. – I(Grants/Research Funding); Zalicus – I(Grants/Research Funding);
  • Zeichner, Joshua, MD: AbbVie – Speaker/Faculty Education(H); Bayer Pharmaceuticals – Speaker/Faculty Education(H); Foamix – A(H); Galderma Laboratories, L.P. – C(H); Johnson & Johnson Consumer Products Company – C(H); L'Oreal USA Inc. – C(H); La Roche-Posay Laboratorie Pharmaceutique – C(H); Pfizer Inc. – A(H), Speaker/Faculty Education(H); Promius Pharma, LLC – A(H); Sanofi/Regeneron – Speaker/Faculty Education(H); Sun Pharmaceutical Industries Ltd. – C(H); Unilever – C(H); Valeant Pharmaceuticals International – A(H);
Schedule
Friday, March 1
9:00 AM
Dr. Kircik and Dr. Zeichner / Introduction
9:05 AM
Dr. Del Rosso / Topical Treatments for Acne
9:25 AM
Dr. Bhatia / Oral Antibiotics for Acne
9:45 AM
Dr. Del Rosso and Dr. Bhatia / Questions and Answers
9:50 AM
Dr. Zeichner / Isotretinoin for Acne
10:10 AM
Dr. Harper / Hormonal Therapy for Acne
10:30 AM
Dr. Kircik / New and Emerging Therapies for Acne
10:50 AM
Dr. Kircik, Dr. Zeichner, and Dr. Harper / Questions and Answers
Event Details
  • Date
    Friday, March 1
  • Time
    9:00 AM - 11:00 AM
  • Location
    Ballroom B
  • CME Credits
    2.00
  • Type
Directors/Co-Directors
  • Leon H. Kircik, MD, FAAD
  • Joshua Zeichner, MD, FAAD
Speakers
  • James Q. Del Rosso, DO, FAAD
  • Julie Claire Harper, MD, FAAD - Handout
  • Neal D. Bhatia, MD, FAAD - Handout